Literature DB >> 8290474

Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

S M Klein1, G W Elmer, L V McFarland, C M Surawicz, R H Levy.   

Abstract

Saccharomyces boulardii (Sb) is a nonpathogenic yeast used to treat intestinal illnesses such as pseudomembranous colitis and antibiotic associated diarrhea. The behavior of this biotherapeutic agent in humans was determined (1) in investigating the effect of dose on the steady-state level and recovery and (2) in quantitating the effect of ampicillin on the recovery and elimination profile. As the Sb dose increased, the mean steady-state concentration of Sb increased significantly. The percentage recovery was dose independent. When a single Sb dose was administered 24 hr after beginning a course of ampicillin, there was a significant increase (P < 0.01) in both the area under the concentration versus time curve and the maximum fecal concentration compared to values obtained without ampicillin. Ampicillin increased steady-state recovery of the drug about twofold (P < 0.05) and steady-state levels about 2.4 times (P < 0.01). These studies have shown that there is a relationship between the dose and the amount of Sb recovered and that perturbation of the GI flora by ampicillin increases steady-state levels of Sb.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8290474     DOI: 10.1023/a:1018924820333

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Survival of Lactobacillus species (strain GG) in human gastrointestinal tract.

Authors:  B R Goldin; S L Gorbach; M Saxelin; S Barakat; L Gualtieri; S Salminen
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

Review 2.  Probiotics in human medicine.

Authors:  R Fuller
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

3.  Disposition kinetics of Saccharomyces boulardii in man and rat.

Authors:  H Blehaut; J Massot; G W Elmer; R H Levy
Journal:  Biopharm Drug Dispos       Date:  1989 Jul-Aug       Impact factor: 1.627

4.  Enzyme-substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase-isomaltase deficiency.

Authors:  H K Harms; R M Bertele-Harms; D Bruer-Kleis
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

5.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

6.  Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Authors:  A V Boddy; G W Elmer; L V McFarland; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

7.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; G Elmer; J Chinn
Journal:  Am J Gastroenterol       Date:  1989-10       Impact factor: 10.864

8.  Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study.

Authors:  C M Surawicz; G W Elmer; P Speelman; L V McFarland; J Chinn; G van Belle
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

9.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

10.  Kinetics of Saccharomyces cerevisiae elimination from the intestines of human volunteers and effect of this yeast on resistance to microbial colonization in gnotobiotic mice.

Authors:  S Pecquet; D Guillaumin; C Tancrede; A Andremont
Journal:  Appl Environ Microbiol       Date:  1991-10       Impact factor: 4.792

View more
  18 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study.

Authors:  S J M Ten Bruggencate; S A Girard; E G M Floris-Vollenbroek; R Bhardwaj; T A Tompkins
Journal:  Eur J Clin Nutr       Date:  2014-11-05       Impact factor: 4.016

Review 3.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

4.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 5.  Microecologic approaches for traveler's diarrhea, antibiotic-associated diarrhea, and acute pediatric diarrhea.

Authors:  L V McFarland
Journal:  Curr Gastroenterol Rep       Date:  1999-08

6.  Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.

Authors:  S Blanquet; J P Meunier; M Minekus; S Marol-Bonnin; M Alric
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

Review 7.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

8.  Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota.

Authors:  Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Sandrine Chalancon; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Appl Environ Microbiol       Date:  2012-11-30       Impact factor: 4.792

9.  Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats.

Authors:  Philippe Girard; Yannick Pansart; Ingrid Lorette; Jean-Marie Gillardin
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

10.  Recombinant Saccharomyces cerevisiae strain expressing a model cytochrome P450 in the rat digestive environment: viability and bioconversion activity.

Authors:  G Garrait; J F Jarrige; S Blanquet; E Beyssac; M Alric
Journal:  Appl Environ Microbiol       Date:  2007-04-06       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.